Pulmonx (LUNG) Stock Price
Pulmonx Price
Revenue has compounded at 74.3% per year over the past 12 years to 90.50 M USD. Pulmonx's net margin stands at -59.7%, up from -100.5% several years earlier. Analysts set a median price target of 4.59 USD, implying 150.8% above the current price. Of 12 analysts, 9 rate the stock a buy — an overall Buy consensus.
Pulmonx stock price
Pulmonx business model & stock analysis
Frequently asked questions about Pulmonx
The business model of Pulmonx Corp focuses on developing and commercializing minimally invasive medical devices for the treatment of severe respiratory diseases. The company specializes in creating novel solutions for conditions like emphysema and chronic bronchitis, offering patients and healthcare providers effective alternatives to traditional treatments. Pulmonx Corp's innovative technologies, such as the Zephyr Valve System, help improve lung function and quality of life for individuals suffering from severe respiratory conditions. With a strong emphasis on research, development, and collaboration, Pulmonx Corp strives to bring about advancements in respiratory care and provide targeted therapies for patients worldwide.
Pulmonx Corp is primarily active in the medical device industry.
The main competitors of Pulmonx Corp in the market are Boston Scientific Corporation and Olympus Corporation.
Pulmonx Corp is a leading medical technology company specializing in minimally invasive devices for patients suffering from severe lung diseases. Established in 1997, Pulmonx has dedicated its efforts to improving the lives of those with chronic obstructive pulmonary disease (COPD) and severe emphysema. The company's innovative products, such as the Zephyr Valve System, offer a novel approach to lung disease treatment, providing patients with a non-surgical option that reduces hyperinflation and improves lung function. Pulmonx Corp has emerged as a global leader in the field, helping patients worldwide breathe easier and enhancing their quality of life.
Pulmonx Corp has achieved significant milestones in its journey. The company developed an innovative solution known as Zephyr Valve, which has revolutionized the treatment of severe emphysema. Pulmonx Corp received FDA approval for Zephyr Valve, making it the first minimally invasive implant to offer lung volume reduction in emphysema patients. This milestone marked a major breakthrough in the field of respiratory care. Additionally, Pulmonx Corp has expanded its global reach and established partnerships with renowned medical centers worldwide. These achievements highlight the company's commitment to improving the lives of patients suffering from debilitating lung diseases.
Pulmonx Corp is primarily present in various countries and regions around the world. These include the United States, Europe, Asia-Pacific, and Latin America.
Pulmonx Corp represents a strong commitment to improving the lives of patients with severe lung diseases. Their corporate philosophy revolves around innovation, patient-centricity, and clinical excellence. The company values inclusivity, collaboration, and integrity in their pursuit of developing novel therapeutic solutions. Pulmonx Corp focuses on providing minimally invasive devices and technologies that offer better treatment options for conditions like chronic obstructive pulmonary disease (COPD) and emphysema. With a mission to enhance lung health, Pulmonx Corp continuously strives to advance medical knowledge, improve patient outcomes, and contribute to global respiratory innovation.
Analysts currently set an average price target of 5.87 USD for the Pulmonx stock (median: 4.59 USD), implying +220.5 % versus the latest price. The consensus is based on 12 analyst ratings.
11 analysts currently rate the Pulmonx stock: 8 recommend buying, 3 holding and 0 selling. For 2026, analysts expect Pulmonx to generate revenue of 90.54 M USD and earnings per share of -1.00 USD.
Converted at the current exchange rate, the Pulmonx share trades at 1.63 EUR (1.83 USD).
The Pulmonx share (LUNG) is listed on 4 stock exchanges, including: NASDAQ (LUNG), Frankfurt (4NI.F), München (4NI.MU), Düsseldorf (4NI.DU).
The company Pulmonx Corp is a leading manufacturer of medical devices that help patients with respiratory diseases. The company is headquartered in Redwood City, California and has branches all over the world. Pulmonx Corp's business model is based on the development, manufacturing, and marketing of products for the treatment of lung and respiratory diseases. There are several business areas that the company serves: 1. Endobronchial therapy Pulmonx Corp has developed a unique procedure for endobronchial therapy, in which a small implant is inserted into the trachea to open the airways. The procedure is particularly effective in patients with severe emphysema or chronic obstructive pulmonary disease (COPD). 2. Diagnostics The company also offers a wide range of diagnostic tests for respiratory diseases. These tests help doctors make the correct diagnosis and plan the best treatment for the patient. 3. Training and education Pulmonx Corp also operates an extensive training and education program for doctors and medical staff. The company offers a variety of workshops and training sessions for endobronchial therapy to ensure that doctors can use the technology safely and effectively. 4. Research and development An important part of Pulmonx's business model is the continuous research and development of new products and technologies for the treatment of respiratory diseases. The company invests significant resources in developing new implants for endobronchial therapy and researching new diagnostic tests. One example of a product offered by Pulmonx Corp is the Zephyr Valve. This is a small, implantable device that is placed in the patient's bronchi. The valve allows the patient to breathe more effectively by improving lung ventilation and expanding the airways. The valve is implanted using an endobronchial catheter and can usually be done on an outpatient basis. Most patients can go home the next day. Overall, Pulmonx Corp's business model has proven to be extremely successful. The company has carved out a unique niche in the respiratory technology market and is on its way to becoming a leading provider of endobronchial therapies and diagnostic tests. The company relies on scientifically based innovations to improve the health of people with respiratory diseases.
The expected revenue of Pulmonx is 90.54 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Pulmonx is -41.51 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Pulmonx is currently -1.83. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Pulmonx stock.
The price-to-sales ratio (P/S) of Pulmonx is currently 0.84. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Pulmonx stock.
The Eulerpool Quality Score for Pulmonx is 4/10.
The ISIN of Pulmonx is US7458481014. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Pulmonx is A2P1AF. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Pulmonx is LUNG. The ticker symbol is used to trade Pulmonx shares on the stock exchange.
Pulmonx stock
Pulmonx Peer Group
Pulmonx Ticker
Pulmonx FIGI
All fundamentals and in-depth analysis of Pulmonx
Our stock analysis for Pulmonx stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pulmonx. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.